Oral controlled-release therapeutics - Otsuka Pharmaceutical/Endo Pharmaceuticals

Drug Profile

Oral controlled-release therapeutics - Otsuka Pharmaceutical/Endo Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otsuka Pharmaceutical; Penwest Pharmaceuticals
  • Developer Endo Pharmaceuticals; Otsuka Pharmaceutical
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Undefined in USA (PO)
  • 25 Jan 2010 A fourth research and development agreement has been signed between Penwest Pharmaceuticals and Otsuka Pharmaceutical
  • 28 Oct 2009 A Penwest formulation completes a phase I pharmacokinetic study
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top